Acute clozapine suppresses synchronized pyramidal synaptic network activity by increasing inhibition in the ferret prefrontal cortex

Journal of Neurophysiology

Volumn 97, Issue 2, 2007, Pages 1196-1208

  Gao, Wen Jun ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; FERRET; IN VITRO STUDY; NERVE CELL STIMULATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SYNAPTIC INHIBITION;

ACTION POTENTIALS; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DATA INTERPRETATION, STATISTICAL; DOPAMINE AGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; FERRETS; INTERNEURONS; MEMBRANE POTENTIALS; NERVE NET; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RECEPTORS, DOPAMINE D4; SYNAPSES;

EID: 33846915665     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00400.2006     Document Type: Article

References (95)

1. Addington AM, Gornick M, Duckworth J, Sporn A, Gogtay N, Bobb A, Greenstein D, Lenane M, Gochman P, Baker N, Balkissoon R, Vakkalanka RK, Weinberger DR, Rapoport JL, Straub RE. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol Psychiatry 10: 581-588, 2005.
2. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234, 1997.
3. Asaumi Y, Hasuo H, Akasu T. Dopamine presynaptically depresses fast inhibitory synaptic transmission via D4 receptor-protein kinase A pathway in the rat dorsolateral septal nucleus. J Neurophysiol 96: 591-601, 2006.
4. Ashby CR Jr, Wang RY. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24: 349-394, 1996.
5. Avoli M, D'Antuono M, Louvel J, Kohling R, Biagini G, Pumain R, D'Arcangelo G, Tancredi V. Network and pharmacological mechanisms leading to epileptiform synchronization in the limbic system in vitro. Prog Neurobiol 68: 167-207, 2002.
6. Azdad K, Piet R, Poulain DA, Oliet SH. Dopamine D4 receptor-mediated presynaptic inhibition of GABAergic transmission in the rat supraoptic nucleus. J Neurophysiol 90: 559-565, 2003.
7. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31: 251-269, 2000.
8. Benes FM, Berretta S. Amygdalo-entorhinal inputs to the hippocampal formation in relation to schizophrenia. Ann NY Acad Sci 911: 293-304, 2000.
9. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25: 1-27, 2001.
10. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12: 924-929, 1992.
11. Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 755: 121-129, 1997.
12. Bourdelais AJ, Deutch AY. The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat: an in vivo microdialysis study. Cereb Cortex 4: 69-77, 1994.
13. Calhoun VD, Kiehl KA, Liddle PF, Pearlson GD. Aberrant localization of synchronous hemodynamic activity in auditory cortex reliably characterizes schizophrenia. Biol Psychiatry 55: 842-849, 2004.
14. Castro-Alamancos MA, Rigas P. Synchronized oscillations caused by disinhibition in rodent neocortex are generated by recurrent synaptic activity mediated by AMPA receptors. J Physiol 542: 567-581, 2002.
15. Chagnac-Amitai Y, Connors BW. Synchronized excitation and inhibition driven by intrinsically bursting neurons in neocortex. J Neurophysiol 62: 1149-1162, 1989.
16. Chen L, Yang CR. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87: 2324-2336, 2002.
17. Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 298: 1418-1421, 2002.
18. Connors BW. Initiation of synchronized neuronal bursting in neocortex. Nature 310: 685-687, 1984.
19. Cossart R, Bernard C, Ben-Ari Y. Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies. Trends Neurosci 28: 108-115, 2005.
20. Daly DA, Moghaddam B. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152: 61-64, 1993.
21. Denney D, Stevens JR. Clozapine and seizures. Biol Psychiatry 37: 427-433, 1995.
22. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29: 250-264, 1999a.
23. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 4: 418-428, 1999b.
24. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 8: 691-709, 1989.
25. Fisahn A, Pike F, Buhl EH, Paulsen O. Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vitro. Nature 394: 186-189, 1998.
26. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 3: 89-97, 1995.
27. Gao WJ, Goldman-Rakic PS. NMDA receptor-mediated epileptiform persistent activity requires calcium release from intracellular stores in prefrontal neurons. Exp Neurol 197: 495-504, 2006.
28. Gao WJ, Krimer LS, Goldman-Rakic PS. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc Natl Acad Sci USA 98: 295-300, 2001.
29. Gao WJ, Wang Y, Goldman-Rakic PS. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J Neurosci 23: 1622-1630, 2003.
30. Gemperle AY, Enz A, Pozza MF, Luthi A, Olpe HR. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 117: 681-695, 2003.
31. Gisabella B, Bolshakov VY, Benes FM. Regulation of synaptic plasticity in a schizophrenia model. Proc Natl Acad Sci USA 102: 13301-13306, 2005.
32. Glenthoj BY, Hemmingsen R. Transmitter dysfunction during the process of schizophrenia. Acta Psychiatr Scand Suppl 395: 105-112, 1999.
33. Grunze H, Rainnie D, Hasselmo M, Barkai E, Hearn E, McCarley R, Greene R. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16: 2034-2043, 1996.
34. Hablitz JJ. Regulation of circuits and excitability: implications for epileptogenesis. Epilepsy Currents 4: 151-153, 2004.
35. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, Sampson AR, Lewis DA. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23: 6315-6326, 2003.
36. Herrmann CS, Demiralp T. Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol 116: 2719-2733, 2005.
37. Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956: 349-357, 2002.
38. Jardemark KE, Ninan I, Liang X, Wang RY. Protein kinase C is involved in clozapine's facilitation of N-methyl-D-aspartate- and electrically evoked responses in pyramidal cells of the medial prefrontal cortex. Neuroscience 118: 501-512, 2003.
39. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9: 984-997, 2004.
40. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J Neurosci 13: 4908-4923, 1993.
41. Kawaguchi Y. Physiological subgroups of nonpyramidal cells with specific morphological characteristics in layer II/III of rat frontal cortex. J Neurosci 15: 2638-2655, 1995.
42. Kawaguchi Y. Distinct firing patterns of neuronal subtypes in cortical synchronized activities. J Neurosci 21: 7261-7272, 2001.
43. Keros S, Hablitz JJ. Ectopic action potential generation in cortical interneurons during synchronized GABA responses. Neuroscience 131: 833-842, 2005a.
44. A conductances in rat neocortex. J Neurophysiol 94: 2073-2085, 2005b.
45. Lee K-H, Williams LM, Breakspear M, Gordon E. Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain Res Rev 41: 57-78, 2003a.
46. Lee KH, Williams LM, Haig A, Gordon E. Gamma (40 Hz) phase synchronicity and symptom dimensions in schizophrenia. Cognit Neuropsychiatry 8: 57-71, 2003b.
47. Lewis DA. Neural circuitry of the prefrontal cortex in schizophrenia. Arch Gen Psychiatry 52: 269-273; discussion 267-268, 1995.
48. Lewis DA. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 31: 270-276, 2000.
49. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324, 2005.
50. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 28: 325-334, 2000.
51. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174: 143-150, 2003.
52. Lidow MS, Goldman-Rakic PS. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci USA 91: 4353-4356, 1994.
53. Lidow MS, Williams GV, Goldman-Rakic PS. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol Sci 19: 136-140, 1998.
54. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 50: 329-338, 1989.
55. Maguire GA. Comprehensive understanding of schizophrenia and its treatment. Am J Health Syst Pharm 59: S4-S11, 2002.
56. Matz R, Rick W, Thompson H, Gershon S. Clozapine - a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res Clin Exp 16: 687-695, 1974.
57. McBain CJ, Fisahn A. Interneurons unbound. Nat Rev Neurosci 2: 11-23, 2001.
58. McCormick DA, Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63: 815-846, 2001.
59. Melone M, Vitellaro-Zuccarello L, Vallejo-Illarramendi A, Perez-Samartin A, Matute C, Cozzi A, Pellegrini-Giampietro DE, Rothstein JD, Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 6: 380-386, 2001.
60. Minabe Y, Watanabe K, Nishimura T, Ashby CR Jr. Acute and chronic administration of clozapine produces greater proconvulsant actions than haloperidol on focal hippocampal seizures in freely moving rats. Synapse 29: 272-278, 1998.
61. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104, 2005.
62. Miyamoto S, LaMantia AS, Duncan GE, Sullivan P, Gilmore JH, Lieberman JA. Recent advances in the neurobiology of schizophrenia. Mol Interv 3: 27-39, 2003.
63. Moghaddam B, Bunney BS. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54: 1755-1760, 1990.
64. Mrzljak L, Bergson C, Pappy M, Huff R, Levenson R, Goldman-Rakic PS. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 381: 245-248, 1996.
65. Ninan I, Jardemark KE, Wang RY. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48: 66-79, 2003.
66. Ortega-Alvaro A, Gibert-Rahola J, Mico JA. Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats. Prog Neuro-Psychopharmacol Biol Psychiatry 30: 104-111, 2006.
67. Pietraszek M, Gołembiowska K, Bijak M, Ossowska K, Wolfarth S. Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn-Schmiedeberg's Arch Pharmacol 366: 417-424, 2002.
68. Pralong E, Magistretti P, Stoop R. Cellular perspectives on the glutamatemonoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol 67: 173-202, 2002.
69. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148: 3-15, 2000.
70. Romo-Parra H, Aceves J, Gutierrez R. Tonic modulation of inhibition by dopamine D4 receptors in the rat hippocampus. Hippocampus 15: 254-259, 2005.
71. Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA. The use of clozapine in neurologic disorders. J Clin Psychiatry 55, Suppl. B: 98-101, 1994.
72. Sanchez-Vives MV, McCormick DA. Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat Neurosci 3: 1027-1034, 2000.
73. Sarter M, Nelson CL, Bruno JP. Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophr Bull 31: 117-138, 2005.
74. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45: 17-25, 1999.
75. Shin R-M, Masuda M, Miura M, Sano H, Shirasawa T, Song W-J, Kobayashi K, Aosaki T. Dopamine D4 receptor-induced postsynaptic inhibition of GABAergic currents in mouse globus pallidus neurons. J Neurosci 23: 11662-11672, 2003.
76. Singer W, Gray C, Engel A, Konig P, Artola A, Brocher S. Formation of cortical cell assemblies. Cold Spring Harb Symp Quant Biol 55: 939-952, 1990.
77. Spencer KM, Nestor PG, Niznikiewicz MA, Salisbury DF, Shenton ME, McCarley RW. Abnormal neural synchrony in schizophrenia. J Neurosci 23: 7407-7411, 2003.
78. Spencer KM, Nestor PG, Perlmutter R, Niznikiewicz MA, Klump MC, Frumin M, Shenton ME, McCarley RW. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci USA 101: 17288-17293, 2004.
79. Squires RF, Saederup E. Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same "core" fraction of GABA(A) receptors. Neurochem Res 23: 1283-1290, 1998.
80. Stevens JR, Denney D, Szot P. Kindling with clozapine: behavioral and molecular consequences. Epilepsy Res 26: 295-304, 1996.
81. Traub RD, Bibbig A, LeBeau FEN, Buhl EH, Whittington MA. Cellular mechanisms of neuronal population oscillations in the hippocampus in vitro. Annu Rev Neurosci 27: 247-278, 2004.
82. van der Stelt O, Belger A, Lieberman JA. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proc Natl Acad Sci USA 101: 17567-17568, 2004.
83. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 77: 501-505, 2002.
84. Wang X, Zhong P, Yan Z. Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. J Neurosci 22: 9185-9193, 2002.
85. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43: 114-124, 1986.
86. Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders. Curr Opin Investig Drugs 2: 940-945, 2001.
87. Whittington MA, Faulkner HJ, Doheny HC, Traub RD. Neuronal fast oscillations as a target site for psychoactive drugs. Pharmacol Ther 86: 171-190, 2000.
88. Whittington MA, Traub RD. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci 26: 676-682, 2003.
89. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 313: 594-603, 2005.
90. Wong RK, Traub RD, Miles R. Cellular basis of neuronal synchrony in epilepsy. Adv Neurol 44: 583-592, 1986.
91. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 95: 5341-5346, 1998.
92. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14: 4159-4166, 1994.
93. Yang CR, Chen L. Targeting prefrontal cortical dopamine d1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 11: 452-470, 2005.
94. Yang CR, Seamans JK, Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21: 161-194, 1999.
95. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23: 250-262, 2000.